Sumitomo Mitsui Trust Group Inc. Sells 4,079 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Sumitomo Mitsui Trust Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 278,120 shares of the biopharmaceutical company’s stock after selling 4,079 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.27% of Regeneron Pharmaceuticals worth $210,890,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $26,000. Armstrong Advisory Group Inc. increased its stake in Regeneron Pharmaceuticals by 466.7% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares in the last quarter. Activest Wealth Management boosted its position in shares of Regeneron Pharmaceuticals by 780.0% in the 3rd quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 39 shares in the last quarter. Alpine Bank Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on REGN shares. UBS Group upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. JPMorgan Chase & Co. boosted their price target on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research report on Tuesday, October 6th. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. HSBC upped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Leerink Partners upped their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $850.83.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Price Performance

REGN opened at $927.89 on Monday. The stock’s fifty day moving average is $793.30 and its 200-day moving average is $738.05. Regeneron Pharmaceuticals, Inc. has a one year low of $591.52 and a one year high of $935.35. The company has a market capitalization of $95.54 billion, a PE ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.66 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $11.83 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the sale, the executive vice president owned 13,134 shares of the company’s stock, valued at $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares in the company, valued at $36,960,559.10. This trade represents a 7.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.